12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Relday risperidone: Interim Phase I data

Top-line data from an open-label, U.S. Phase I trial in 30 patients with chronic, stable schizophrenia or schizoaffective disorder showed that single doses of 25 and 50 mg once-monthly subcutaneous Relday produced a "favorable safety and PK profile." Zogenix said adverse events were generally mild to moderate and consistent with other...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >